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Abstract
Background: Monitoring local malaria transmission intensity is essential for planning evidence-based control
strategies and evaluating their impact over time. Anti-malarial antibodies provide information on cumulative
exposure and have proven useful, in areas where transmission has dropped to low sustained levels, for retrospectively
reconstructing the timing and magnitude of transmission reduction. It is unclear whether serological markers are
also informative in high transmission settings, where interventions may reduce transmission, but to a level where
considerable exposure continues.
Methods: This study was conducted through ongoing KEMRI and CDC collaboration. Asembo, in Western Kenya, is an
area where intense malaria transmission was drastically reduced during a 1997–1999 community-randomized, controlled
insecticide-treated net (ITN) trial. Two approaches were taken to reconstruct malaria transmission history during the
period from 1994 to 2009. First, point measurements were calculated for seroprevalence, mean antibody titre, and
seroconversion rate (SCR) against three Plasmodium falciparum antigens (AMA-1, MSP-119, and CSP) at five time
points for comparison against traditional malaria indices (parasite prevalence and entomological inoculation rate).
Second, within individual post-ITN years, age-stratified seroprevalence data were analysed retrospectively for an
abrupt drop in SCR by fitting alternative reversible catalytic conversion models that allowed for change in SCR.
Results: Generally, point measurements of seroprevalence, antibody titres and SCR produced consistent patterns
indicating that a gradual but substantial drop in malaria transmission (46-70%) occurred from 1994 to 2007, followed by
a marginal increase beginning in 2008 or 2009. In particular, proportionate changes in seroprevalence and SCR point
estimates (relative to 1994 baseline values) for AMA-1 and CSP, but not MSP-119, correlated closely with trends in parasite
prevalence throughout the entire 15-year study period. However, retrospective analyses using datasets from 2007, 2008
and 2009 failed to detect any abrupt drop in transmission coinciding with the timing of the 1997–1999 ITN trial.
Conclusions: In this highly endemic area, serological markers were useful for generating accurate point estimates
of malaria transmission intensity, but not for retrospective analysis of historical changes. Further investigation,
including exploration of different malaria antigens and/or alternative models of population seroconversion, may
yield serological tools that are more informative in high transmission settings.
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Background
Measuring local malaria transmission intensity is critical
for estimating the magnitude of malaria disease burden,
planning evidence-based control strategies and evaluating
the impact of interventions [1-3]. Moreover, malaria con-
trol programmes would benefit from monitoring long-
term changes in transmission intensity in order to adapt
control strategies to evolving local conditions [4]. No con-
sensus exists, however, on which methods are most appro-
priate for programmatic monitoring of malaria endemicity
over time, as all current tools have drawbacks [2,4].
Hospital-based surveillance records may be readily avail-
able, but are considered unreliable as experts estimate that
fewer than 20% of malaria cases and deaths are reported
to the formal health system [4-6]. Inaccuracies are further
compounded by presumptive diagnosis at health centres,
leading to overestimation of malaria cases among those
individuals seeking care [6,7]. Entomological inoculation
rate (EIR), which describes the average rate at which in-
dividuals are bitten by infective mosquitoes, is the most
direct indicator of malaria transmission intensity [8,9].
Unfortunately, measuring EIR is difficult and labour-
intensive [10], and estimates can lack precision due to
small-scale spatial and/or temporal heterogeneity in
mosquito distributions [9,11,12]. In addition, EIR over-
estimates force of infection, the number of new infec-
tions per person per unit time, due to heterogeneous
biting by mosquitoes [13,14]. Parasite prevalence, the
proportion of individuals with detectable Plasmodium
parasites, is another common metric of malaria risk.
Parasite prevalence is not a measure of incidence, how-
ever, and its relationship with force of infection is com-
plicated by super-infection and acquired immunity [15].
Furthermore, estimates of parasite prevalence can vary
widely in areas of seasonal transmission, and are influ-
enced by the method of parasite detection, timing of
measurement during the course of infection and access
to anti-malarial drugs [13,16,17].
Anti-malarial antibodies are markers of past infection
that can help to elucidate temporal trends in transmis-
sion [18,19]. Because antibodies are longer lasting com-
pared to patent parasitaemia and the lifespan of infective
mosquitoes, serological tools are potentially more sensi-
tive and robust than parasite prevalence or EIR. Large-
scale serological surveys have proven useful in the past
for examining impacts of interventions that reduce
malaria parasite exposure. During the Garki Project in
northern Nigeria, antibody prevalence and levels reflected
recent changes in malaria exposure. Antibody responses
fell abruptly during the intervention phase of the study,
but rebounded soon after the intensive intervention was
stopped [20]. More recently, by fitting a reversible cata-
lytic conversion model to age-stratified seroprevalence
data, investigators have estimated seroconversion rates
(SCRs) that are analogous to force of infection [16,18].
SCRs generated from several locations in Africa
[16,21,22], Asia [23] and the Pacific [24] have shown
close correlation with independent measures of trans-
mission intensity such as malaria incidence among in-
fants and young children, as well as averaged parasite
prevalence and EIR values.
Because serological markers provide information on
cumulative exposure over time [25], they are particularly
well suited for evaluating long-term transmission trends
[16,18]. Data from a single cross-sectional serological
survey can, in theory, be used to generate a point esti-
mate of the current force of infection as well as ana-
lyse historic changes in exposure to infection [16,18].
Sero-epidemiological studies from Tanzania [21], Vanuatu
[24], Equatorial Guinea [22], and Swaziland [26] have
confirmed that historic reductions in local malaria
transmission (e.g., due to successful control strategies) can
be demonstrated by a significantly lower SCR among
younger cohorts born after the intervention(s). In these
cases, age-seroprevalence curves exhibited a ‘break point’
signalling the timing of the change in SCR without the
need for comparison against a baseline survey. To date,
studies employing this method to reconstruct the timing
and magnitude of transmission reduction have come from
areas where transmission has dropped to low, sustained
levels [21,22,24,26]. It is unclear whether these serological
tools are informative for reconstructing long-term malaria
trends in regions of high transmission, where interven-
tions may reduce transmission, but to a level where con-
siderable exposure continues.
The purpose of this study was to investigate the utility
of serological markers of Plasmodium falciparum expos-
ure for estimating force of malaria infection and detect-
ing temporal changes in malaria risk over an extended
period in a highly endemic setting. Asembo, in Western
Kenya, has historically experienced intense malaria trans-
mission year round [27]. A community-randomized, con-
trolled insecticide-treated net (ITN) trial conducted from
1997 to 1999 drastically reduced malaria transmission
[28,29]. Following the trial, continued high ITN coverage
[30], coupled with expanded malaria interventions and
health system and socio-economic improvements, led to
further reductions in malaria morbidity and mortality from
the late 1990s to late 2000s [31]. Despite these gains, how-
ever, malaria transmission in Asembo remains high [31].
For this study, three antigens spanning a range of im-
munogenicities were selected in order to identify at least
one marker with sensitivity appropriate for the transmis-
sion intensities observed in Asembo. Immune responses
against circumsporozoite protein (CSP) are considered
short-lived, as sporozoites from each infective bite are
present in the blood in small numbers and for only a
short duration [32]. For this reason, anti-CSP antibodies
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are likely to underestimate malaria endemicity in low
transmission areas [25], but be sensitive in hyper- and
holo-endemic settings [33,34]. The blood-stage antigen
merozoite surface protein-119 (MSP-119) exhibits mod-
erate immunogenicity and has been useful for estimat-
ing malaria endemicity across a range of low, moderate,
and high transmission settings in Africa [18,35]. Apical
membrane antigen-1 (AMA-1), a blood-stage antigen
known to be highly immunogenic, elicits a long-lived im-
mune response that may cause population antibody re-
sponses to saturate at moderate transmission levels [18].
Two approaches were taken to reconstruct malaria
transmission history in Asembo. First, point measurements
of serological responses were calculated at five time points
between 1994 and 2009, covering the period before the
ITN trial to roughly a decade after the trial, for comparison
against traditional malaria indices (parasite prevalence
and EIR). Point measurements were also compared be-
tween villages that received ITNs in 1997 vs 1999 to
understand if serological responses would reflect small
differences in the length of population protection
under ITNs. Second, within individual post-ITN years,
age-seroprevalence curves were examined to look retro-
spectively for an abrupt drop in SCR corresponding to
the timing of the ITN trial.
Methods
This research was conducted through ongoing collaboration
between the Kenya Medical Research Institute (KEMRI)
and the Centers for Disease Control and Prevention (CDC).
Study site
Asembo is located on the northern shores of Lake
Victoria in Siaya County, Western Kenya. This lowland
rural area (elevation 3,700 m) has served as the site of
several malaria epidemiology studies and has been de-
scribed in detail [27,28,30]. During the early 1990s, para-
site prevalence in children aged < five years was 70-80%
year round [36]. Plasmodium falciparum accounted
for >95% of all clinical malaria infections [27,36]. Predom-
inant malaria vectors in the region included Anopheles
gambiae s.s., Anopheles funestus and Anopheles arabiensis,
with estimated EIRs ranging from 60 to 300 infective bites
per person per year [37,38].
During the community-randomized trial carried out in
Asembo from 1997 to 1999 [28], 40 of 79 villages were
randomized to receive ITNs and the rest served as con-
trols until 1999, after which they also received ITNs
[29]. The two-year trial resulted in a 74% reduction in
malaria force of infection [39] and >90% reduction in
EIR [40] in intervention villages compared to control vil-
lages. After the trial, ITN coverage was maintained at
high levels [30]. ITNs were replaced periodically, and
were retreated with a pyrethroid formulation at six- to
nine-month intervals by KEMRI/CDC through 2007
(J Gimnig, unpublished data). In addition, the Kenya
Ministry of Health promoted scale-up of ITNs throughout
this region, first through subsidized ITN distribution at
antenatal clinics beginning in 2004, and later through a
mass campaign distributing free long-lasting ITNs to all
children aged < five years in 2006 [31].
Entomological inoculation rates
Data on the number of blood-fed An. gambiae s.s., An.
arabiensis and An. funestus captured, the number of
houses sampled and the number of residents per house,
were obtained from prior studies to estimate annual
EIRs. Household mosquito collections have been con-
ducted in Asembo since 1993, but sampling methods
and trapping techniques have varied depending on the
particular study in place. Bed net traps were used to col-
lect anophelines from 1993 to 1996 [27,32]. From 1997
to 2001, entomological collections were made by pyreth-
rum spray catch (PSC) [30,40,41]. Indoor CDC light
traps were employed during the period from 2002 to
2007 [42,43]. Since 2008, mosquito collections have
again been conducted using PSCs (J Gimnig, unpub-
lished data). For all entomological collections, anophe-
lines were identified, sorted by sex and abdominal status
and dried in individual tubes for laboratory analysis.
Mosquitoes were tested for sporozoite infection by
enzyme-linked immunosorbent assay (ELISA) [44] and
a subset of all specimens classified as An. gambiae s.l.
was identified to sibling species (An. gambiae s.s. or An.
arabiensis) by polymerase chain reaction (PCR) [45].
Parasite prevalence
Annual parasite prevalence for children aged one to five
years was calculated using blood film data from past sur-
veys [27,30,31]. During all surveys, finger-prick blood
samples were collected onto slides, stained with Giemsa
and then examined under a microscope for asexual P.
falciparum parasites. Parasites were enumerated against
300 white blood cells (prior to 1996) or 500 white blood
cells (since 1996). Individuals included in parasite preva-
lence calculations were restricted to those for whom
serological specimens (see below) were also available.
Serological specimens
Serological analyses were conducted using banked samples
collected in 1994, 2000, 2007, 2008 and 2009. Samples
from infants less than one year of age were excluded in all
years to limit confounding of test results by maternal anti-
bodies. Samples from 1994 were collected from a subset of
15 villages in Asembo [27], whereas samples from later
years were collected across the entire Asembo area [30,43].
In 1994 and 2000, capillary blood samples were collected
into tubes and centrifuged to separate serum [27,30],
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which was stored at −80°C until used for ELISAs. Im-
mediately prior to serological testing, serum was diluted
1/200 in reconstitution buffer (phosphate buffered saline
with 0.05% Tween 20 [PBS-T] containing 0.1% sodium
azide).
Specimens from 2007, 2008 and 2009 were collected
as dried blood spots on filter paper [46] during annual
surveys conducted within the KEMRI/CDC Health and
Demographic Surveillance System [31,43,47]. A 3-mm
blood spot was punched from each filter paper and anti-
bodies were eluted in reconstitution buffer as previously
described [21]. The reconstituted blood spot solution,
equivalent to a 1/200 dilution of serum, was stored at 4°C
until used for ELISAs.
Enzyme-linked immunosorbent assays
All samples (sera and reconstituted blood spots) were
tested by ELISA [16,18] for total IgG antibodies against
recombinant P. falciparum AMA-1 (3D7; Biomedical
Primate Research Center, Rijswijk, The Netherlands),
MSP-119 (Wellcome strain; CTK Biotech, San Diego,
CA, USA) and CSP (Gennova Biopharmaceuticals, Pune,
India). Briefly, recombinant AMA-1 (0.4ug/mL), MSP-119
(0.2ug/mL) and CSP (1.6ug/mL) were coated onto
Immunolon-4 microtiter plates (Thermo Fisher Scientific,
Waltham, MA, USA). The following day, plates were
washed in PBS-T, blocked with 1% milk powder (Marvel,
UK) in PBS-T (PBS-T/milk), and then incubated with
samples. All samples were tested in duplicate, with
final serum dilutions at 1/2,000 for AMA-1, 1/1,000
for MSP-119 and 1/200 for CSP. Each ELISA plate also
included blank wells (PBS-T/milk only) and a positive
control dilution series (pooled sera from six hyper-
immune individuals from the Kisumu Blood Bank). On
the third day, unbound antibodies were removed by
washing in PBS-T, samples were incubated with
peroxidase-conjugated rabbit anti-human IgG antibody
(Dako, Carpinteria, CA, USA) (1/5,000 in PBS-T) and
then plates were developed by adding o-phenylenediamine
dihydrochloride (OPD) substrate (Sigma-Aldrich, St Louis,
MO, USA). OPD reactions were held in the dark and
stopped using 2 M H2SO4 after 11 min for AMA-1 and
MSP-119, and 16 min for CSP. Optical density (OD)
was read immediately at 492 nm using a plate reader
(Molecular Devices SpectraMAX 340 and SoftMax Pro
5.4.1 software, Sunnyvale, CA, USA).
Data management and statistical analysis
Duplicate OD values for each sample were imported into
Microsoft Excel (Microsoft, Redmond, WA, USA), aver-
aged and normalized against values from blank wells to
adjust for background reactivity. Samples were excluded
from analysis if duplicate ODs differed by over 50%. Ti-
tration curves were fit to the positive control dilution
series on each plate in order to adjust sample OD values
for plate-to-plate variation and allow for calculation of
titres. Antibody titre was estimated using the formula:
titre = dilution/[maximum OD/(OD test serum – minimum
OD)-1]. Using a mixture model, cut-off values for sero-
positivity were determined separately for each antigen
(AMA-1, MSP-1 and CSP) during each year (1994,
2000, 2007, 2008 and 2009) to avoid direct quantitative
comparison of ELISA results from samples collected by
different methods (serum vs dried blood spot). Briefly,
OD values were fit by maximum likelihood as two
Gaussian distributions [46] and the cut-off value was
assigned as three standard deviations above the mean
of the lower distribution.
To identify differences in seropositivity by sex, blood
film result, or year in which the village received ITNs, lo-
gistic regression models were fit using PROC GENMOD
in SAS 9.3 (SAS Institute, Cary, NC, USA). Age (continu-
ous variable, cube root-transformed) and survey year were
included to control for their effects, and models were
adjusted for clustering of observations from the same
household compound by incorporating an exchangeable
correlation matrix.
Because data from 2000 were limited to children aged
one to five years, a preliminary analysis was conducted
to compare seroprevalence across the five time points
specifically in this young age group. Year to year differ-
ences in the proportion of children seropositive were
evaluated using Z-tests with Bonferroni correction for
multiple comparisons. To calculate a measure analogous
to SCR but using only data from this age group, linear
regression models were fit, using median centile age as
the predictor and centile seroprevalence as the outcome,
to estimate the rate of increase in seroprevalence with
age. This allowed for comparison of transmission inten-
sity between years without making assumptions regard-
ing missing older age groups. All regression lines were
forced through the origin (intercept = 0) and regression co-
efficients were estimated in R version 3.2.0 (R Foundation
for Statistical Computing, Vienna, Austria). Differences in
geometric mean antibody titres (GMT) were also examined
because antibody levels may respond more quickly to re-
cent shifts in transmission than seroprevalence [22,48]. To
visualize distributions of antibody titres in more detail, re-
verse cumulative distribution plots were used, showing
log10–transformed antibody titre on the X-axis and the
percentage of individuals having the indicated antibody
titre or higher on the Y-axis [49]. Differences in anti-
body titres between years were identified by Wilcoxon
rank-sum test with Bonferroni correction.
To estimate population-wide SCRs in Asembo at each
time point, data from all available age groups were used.
Reversible catalytic conversion models were fit to age-
stratified seroprevalence data using maximum likelihood
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Table 1 Demographic characteristics for persons sampled in Asembo by year (% [n])
1994 2000 2007 2008 2009
(n = 636) (n = 629) (n = 169) (n = 173) (n = 1,038)
Age (in years) 1 to 5 63.4 (403) 100 (629) 42.0 (71) 39.3 (68) 24.8 (257)
6 to 15 17.6 (112) 0 (0) 58.0 (98) 60.7 (105) 29.2 (303)
16 to 90 19.0 (121) 0 (0) 0 (0) 0 (0) 46.0 (478)
Sex Female 64.3 (409) 54.1 (340) 49.4 (80) 42.1 (67) 56.9 (590)
Male 35.7 (227) 45.9 (289) 50.6 (82) 57.9 (92) 43.1 (446)
Not recorded 0 0 7 14 2
Blood film resulta Positive 80.5 (418) 54.2 (341) 36.0 (59) 42.9 (72) 36.3 (377)
Negative 19.5 (101) 45.8 (288) 64.0 (105) 57.1 (96) 63.7 (661)
Not recorded 117 0 5 5 0
Year village 1997b 47.2 (300) 47.2 (297) 42.1 (69) 43.6 (75) 48.1 (498)
received ITNs 1999c 52.8 (336) 52.8 (332) 57.9 (95) 56.4 (97) 51.9 (538)
Not recorded 0 0 5 1 2
Source of samples Asembo Bay Cohort Projectd,e ITN follow-up studyf KEMRI/CDC parasitaemia
and anaemia surveyg
KEMRI/CDC parasitaemia
and anaemia surveyg
KEMRI/CDC parasitaemia
and anaemia surveyg
Survey months April to June May to June April April March to April
aAsexual P. falciparum parasites detected by microscopy.
bAt the time of the survey, resided in a village that received ITNs at start of trial in 1997.
cAt the time of the survey, resided in a village that received ITNs at end of trial in 1999.
dBloland et al. [27].
eBloland et al. [36].
fLindblade et al. [30].
gHamel et al. [31].
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in Stata 11 (StataCorp, College Station, TX, USA)
[16,18]. Seroreversion rates for each antigen were con-
strained for the Asembo population by first fitting a glo-
bal model to aggregate data from all years. Individual
models were then fit separately to datasets from each
year to estimate year-specific SCRs. EIR equivalents
(serology-based EIR estimates) were calculated from
AMA-1 and MSP-119 results using previously developed
log-log calibration curves that relate SCRs to EIR values
[16,18]. EIR equivalents could not be calculated from
CSP SCRs because CSP calibration curves have not yet
been developed.
Datasets from years after the ITN trial concluded were
examined for temporal changes in force of infection by
fitting alternative reversible catalytic conversion models
in which the SCR was allowed to change at a single time
point. The significance of each change was evaluated
using a likelihood ratio test against the initial model with
no change in SCR [16,21].
Ethical review
Ethical approval for serological analyses was obtained
from the KEMRI Ethical Review Committee and the
CDC Institutional Review Board.
Results
Demographic data for persons sampled from Asembo
are summarized in Table 1. Differences in study proto-
cols led to variation in the number and age distribution
of individuals sampled during each year. Individuals
from 1994 included a higher proportion of females com-
pared to other years (χ2 = 34.6, p < 0.001) because preg-
nant females were the only persons older than 15 years
surveyed that year. When pregnant females were ex-
cluded in 1994, this difference was no longer observed.
The proportion of individuals with positive blood films
ranged from >80% in 1994 to 36% in 2007. No year to
year differences were observed in the proportion of in-
dividuals residing in villages that received ITNs at the
trial’s start in 1997 vs at the trial’s conclusion in 1999
(χ2 = 3.1, p = 0.533).
Across all years, the likelihood of individuals testing
seropositive increased with age for all three antigens
(AMA-1 OR = 6.0 [95% CI: 4.4-8.0], MSP-119 OR = 2.2
[95% CI: 1.9-2.5], CSP OR = 3.0 [95% CI: 2.5-3.5], p < 0.001
for all). Seropositivity was also associated with positive
blood film for AMA-1 (OR = 3.7 [95% CI: 3.0-4.5], p <
0.001) and CSP (OR = 1.8 [95% CI: 1.4-2.3], p < 0.001),
but not for MSP-119 (OR = 1.0 [95% CI: 0.8-1.2], p = 0.998).
Females were more likely to be seropositive against
MSP-119 (OR = 1.4 [95% CI: 1.1-1.7], p = 0.001), whereas
sex had no effect for AMA-1 (OR = 1.1 [95% CI: 0.9-1.3],
p = 0.540) or CSP (OR = 1.2 [95% CI: 1.0-1.4], p = 0.133).
Whether an individual resided in a village that received
ITNs in 1997 or 1999 had no impact on seropositivity
against any of the three antigens (AMA-1 OR = 0.9
[95% CI: 0.7, 1.1], p = 0.352; MSP-119 OR= 1.0 [95% CI: 0.8-
1.2], p = 0.834; CSP OR= 0.8 [95% CI: 0.7-1.1], p = 0.144).
Serological results for young children
Seroprevalence
Figure 1A shows seroprevalence among young children
compared with parasite prevalence at each time point.
AMA-1 exhibited the highest seroprevalence of the three
antigens tested; within each year, AMA-1 seroprevalence
was typically two- to four-fold greater than that for
MSP-119 or CSP. AMA-1 seroprevalence fell between
1994 and 2000 (p < 0.001), and then again between 2000
and 2007 (p = 0.002). Seroprevalence against MSP-119
and CSP also decreased steadily from 1994 to 2007, but
the year-to-year differences were not statistically signifi-
cant (p > 0.013 for all [cut-off with Bonferroni correc-
tion]). This trend of falling seroprevalence began to
reverse in 2008 for MSP-119 and in 2009 for AMA-1
and CSP, but none of these subsequent changes were
statistically significant (p > 0.013 for all). Across the entire
study period, AMA-1 seroprevalence values corresponded
very closely to parasite prevalence values. Furthermore,
proportionate changes in both AMA-1 and CSP sero-
prevalence (relative to baseline values from 1994) closely
mirrored the pattern observed for parasite prevalence
(Figure 1B). Proportionate changes in MSP-119 seropreva-
lence did not follow the pattern observed for parasite
prevalence, particularly in 2008 and 2009.
To approximate seroconversion rates using only data
from young children, linear regression coefficients (βs)
were calculated to describe the increase in seropreva-
lence per year of age (Figure 2A). Overall, βs for each
antigen exhibited similar patterns as seen for seropreva-
lence (Figure 1A). Proportionate changes in AMA-1 and
CSP βs were similar to those observed for parasite preva-
lence, whereas proportionate changes in MSP-119 βs were
not (Figure 2B). Within each year, no statistically signifi-
cant difference in β was observed between individuals res-
iding in villages that received ITNs in 1997 vs 1999
(Additional file 1).
Antibody levels
Geometric mean antibody titres for children one to five
years of age are displayed in Figure 3A. Reverse cumula-
tive distribution plots, showing the range of observed
antibody titres on the X-axis and the proportion of indi-
viduals exhibiting each titre or higher on the Y-axis, are
presented in Figures 3B-D. The magnitude of year-to-
year change in antibody titres was greatest for AMA-1.
In 2000, surprisingly, antibody titres against MSP-119 were
higher in villages that received ITNs in 1997 (GMT= 25.4
[95% CI: 22.8-28.2]) compared with villages that
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received ITNs in 1999 (GMT= 19.3 [95% CI: 17.4-21.3])
(p >0.001). No differences were detected between villages
receiving ITNs in 1997 vs 1999 for any other antigens.
Antibody titres against all three antigens fell between 1994
and 2000 (p <0.001 for all antigens). For AMA-1, titres fell
further in 2007 (p <0.001), exhibited no change in 2008
(p = 0.026 [cut-off with Bonferroni correction: p = 0.013]),
and then subsequently increased in 2009 (p = 0.004).
MSP-119 titres changed little between 2000 and 2007
(p = 0.148), but increased in 2008 (p <0.001) and then
remained static in 2009 (p = 0.029). CSP titres did not
change from 2000 to 2007 (p = 0.128), but increased in
2008 (p <0.001) and again in 2009 (p <0.001).
Serological results for all age groups
Population SCRs
Results from reversible catalytic conversion models fit
to data from all available age groups are presented in
Figure 4. Seroreversion rates in the Asembo population
were fixed at 0.050 yr−1 for AMA-1, 0.051 yr−1 for
MSP-119 and 0.073 yr
−1 for CSP, based on a preliminary
model fit to data from all years. Consistent with the
results from young children, population-wide immune
responses were strongest against AMA-1. Year-specific
SCRs were roughly an order of magnitude greater for
AMA-1 than for MSP-119 and CSP across the entire
study period. SCRs for all antigens were highest in
1994, before ITN introduction. Although concerns have
been raised that anti-malarial antibody responses in
pregnant women may differ systematically from those
of the general population [50,51], removing pregnant
women from the 1994 analysis had no significant effect
on SCRs (Additional file 2). All subsequent compari-
sons using the 1994 dataset include samples from preg-
nant women.
No statistical differences in SCRs were observed for
individuals living in villages that received ITNs in 1997
vs 1999 (Additional file 3), so within each year, data
from all villages were combined for analysis. For AMA-1,
SCR fell dramatically between 1994 and 2000, and
again between 2000 and 2007 (Figure 4A). AMA-1 SCR
remained unchanged in 2008 and then increased signifi-
cantly in 2009. For MSP-119, no change was observed be-
tween 1994 and 2000, but SCR fell significantly between
A)
B)
Figure 1 Trends in seroprevalence compared with parasite prevalence. A) Seroprevalence (95% CI) and parasite prevalence (95% CI) were
calculated for children aged one to five years in Asembo. B) Ratios of seroprevalence and parasite prevalence relative to baseline values from 1994.
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2000 and 2007 (Figure 4B). In 2008 and 2009, MSP-119
SCR rose slightly, but this trend was not statistically
significant. SCRs for CSP decreased gradually between
each time point from 1994 to 2008, before increasing
again in 2009 (Figure 4C), but none of these changes
were statistically significant. Proportionate changes in
AMA-1 and CSP SCRs (relative to baseline values from
1994) correlated closely with the pattern observed for
parasite prevalence (Figure 4D). Proportionate changes
in MSP-119 SCR, on the other hand, were high com-
pared to parasite prevalence in 2000, 2008, and 2009.
EIR equivalents
Figure 5A shows EIR equivalents estimated from AMA-1
and MSP-119 SCRs compared with EIR values previ-
ously measured in Asembo at the five time points [30]
(J Gimnig, unpublished data). EIR equivalents based on
AMA-1 showed greater variability over the study period
compared to those based on MSP-119. Neither antigen,
however, produced EIR equivalents that closely tracked
observed EIRs, or proportionate changes in EIR values,
over the study period (Figure 5B).
Changes in SCR
Because only young children, one to five years of age,
were surveyed in 2000, this limited dataset could not be
reliably assessed for temporal changes in SCR. For the
remaining post-ITN trial datasets (2007, 2008 and 2009),
none of the age-seroprevalence curves exhibited a break
point suggestive of a past shift in SCR. For each antigen
during each year, the initial model with only a single
SCR provided a better fit than any alternative model
allowing for a change in SCR.
Discussion
Serological markers of P. falciparum exposure were use-
ful for monitoring long-term changes in malaria trans-
mission intensity in this highly endemic region. Patterns
A)
B)
Figure 2 Rate of increase in seroprevalence with age. A) Linear regression coefficients (95% CI) describing the increase in seroprevalence per
year of age among children aged one to five years in Asembo. Regression coefficients were calculated to approximate seroconversion rates using
only data from young children. B) Ratios of regression coefficients and parasite prevalence relative to baseline values from 1994.
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in point measurements of seroprevalence, antibody titres
and SCRs all indicate that a gradual but substantial drop
in malaria transmission (46-70%) occurred in Asembo
from 1994 to 2007, followed by a marginal increase be-
ginning in 2008 or 2009. This is consistent with previous
findings based on child mortality, parasite prevalence
[31] and EIR (J Gimnig, unpublished data). In particular,
proportionate changes in antibody responses, relative to
1994 baseline values, for AMA-1 and CSP (but not
MSP-119) corresponded closely with trends in parasite
prevalence throughout the 15-year study period.
AMA-1 is known to be highly immunogenic [18]; it was
expected that AMA-1 immunological responses would
saturate in the Asembo population, causing seropreva-
lence and SCR to remain static and therefore, uninforma-
tive. This was not the case, as AMA-1 seroprevalence and
SCR varied three-fold between 1994 and 2008. Further-
more, proportionate changes for both AMA-1 seropreva-
lence and SCR exhibited a straightforward relationship
with changes in parasite prevalence over the entire study
period. As anticipated in this highly endemic region, CSP
was also found to be a sensitive marker for detecting
shifts in transmission; proportionate changes in CSP
seroprevalence and SCR generally corresponded well
with changing patterns in parasite prevalence. Despite
having been informative across a range of malaria trans-
mission settings throughout Africa [18,35], MSP-119
performed poorly in Asembo; proportionate changes in
MSP-119 seroprevalence and SCR overestimated changes
in parasite prevalence during 2000, 2008 and 2009.
Examination of antibody titres also revealed an unex-
pected outcome for MSP-119. In 2000 (immediately after
the conclusion of the ITN trial), young children from
villages that received ITNs in 1997 had significantly
higher MSP-119 antibody levels compared with those
from villages that received ITNs in 1999. Previous investi-
gations on short-term immunologic responses in very
young children in Asembo also reported counter-intuitive
results for MSP-119. During a 1992–1994 cohort study fol-
lowing children from birth to 2.5 years, Singer et al. [32]
found an inverse relationship between malaria exposure
(based on EIR and incidence of parasitaemia) and MSP-
119 antibody levels. In 1998, Kariuki et al. [52] reported
that among children under three years of age, seropreva-
lence against MSP-119 was higher in intervention villages
compared with control villages 14 months after the ITN
A) B)
C) D)
Figure 3 Trends in antibody titres. A) Geometric mean titres (95% CI) for children one to five years of age. Reverse cumulative distribution
plots for: B) AMA-1, C) MSP-119 and D) CSP. Each plot shows antibody titres (log10-transformed) on the X-axis and the proportion of individuals
exhibiting that titre or higher on the Y-axis.
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trial’s start. At 22 months after the start of the trial, how-
ever, this pattern was no longer observed. Results from
the current study, together with those of Singer et al. [32]
and Kariuki et al. [52], indicate that MSP-119 is not a reli-
able short- or long-term marker of changing malaria ex-
posure in Asembo. Singer et al. [32] and Kariuki et al.
[52] hypothesized that in this area of intense year-round
malaria transmission, immune systems of young children
may be so overwhelmed by high-density parasitaemia that
reducing parasite exposure leads to a higher immune re-
sponse against blood-stage antigens. Findings for AMA-1
from the present study suggest that this is not true for all
blood-stage antigens, but rather an irregularity of the
MSP-119 response. This hypothesis of ineffective MSP-1
response may also explain why MSP-1 seroprevalence, un-
like that of AMA-1 and CSP, was not correlated with posi-
tive blood film, an indicator of recent infection.
When comparing villages that received ITNs in 1997
vs 1999, it was anticipated that differences in serological
responses would be apparent in 2000 and then gradually
erode with time. Interestingly, aside from the unex-
pected finding of higher MSP-119 antibody titres among
children from villages that received ITNs earlier, no sero-
logical differences were found between the two groups in
2000 or in any other year. This finding suggests that
immune challenge by malaria parasites remains high
enough in this region to maintain antibodies against the
three antigens examined, making it difficult to detect sub-
tle differences in the length of population protection
under ITNs using these serological markers.
The different serological outcomes analysed (sero-
prevalence, increase in seroprevalence with age, antibody
titre, and SCR) all produced similar trends for recon-
structing transmission history in Asembo. Of note, linear
regression proved to be a useful analysis tool. The rela-
tionship between seroprevalence and age tends to be
linear in young age groups, and linear regression allowed
for calculation of an SCR proxy using only data from
children aged one to five years. The fact that these linear
regression coefficients exhibited the same pattern over
time as SCRs estimated using data from all age groups
supports the idea that, in regions of high malaria trans-
mission intensity, immunological changes are most evi-
dent in young children. For example, during the classic
Garki study in northern Nigeria, Cornille-Brogger et al.
[20] also found that changes in antibody levels were
most pronounced in young children up to four years of
age. In Asembo, periodic point estimates of seropreva-
lence against AMA-1 and/or CSP in young children ap-
pear to be adequate for reconstructing long-term changes
A) B)
C) D)
Figure 4 Trends in age-seroprevalence curves and seroconversion rates (SCRs). SCRs (95% CI) were estimated for the Asembo population
by fitting reversible catalytic conversion models to data from all available age groups for: A) AMA-1, B) MSP-119 and C) CSP. D) Ratios of SCR and
parasite prevalence relative to baseline values from 1994.
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in malaria exposure. A major disadvantage, however, of
any analysis method relying on point estimates is that
baseline values plus several subsequent time point mea-
surements are required for comparison. A more powerful
analysis method, particularly in settings where baseline
measurements are unavailable, involves fitting the revers-
ible catalytic conversion model to seroprevalence data
from all age groups to retrospectively detect changes
within a single cross-sectional survey.
The reversible catalytic conversion model generated ac-
curate population-wide SCR estimates, but did not detect
retrospective changes associated with the 1997–1999 ITN
trial within individual post-trial surveys. Because EIR,
parasite prevalence and child mortality statistics from
Asembo all indicated that malaria transmission declined
drastically as a result of the ITN trial [30,39,40,53], chil-
dren born after the trial were expected to exhibit a mark-
edly reduced SCR compared with older age groups.
However, no break points indicating change in SCR with
age were found within the age-seroprevalence curves from
2007, 2008 or 2009. It is possible that changes in SCR
would have been most pronounced immediately after the
trial’s conclusion. Unfortunately, the serological samples
from 2000 were restricted to young children aged one to
five years, limiting the ability to assess for shifts in SCR
across different age groups during that year.
Inability to detect break points in the 2007, 2008 or
2009 age-seroprevalence curves may be due to several
non-mutually exclusive factors. First, the Kenya Ministry
of Health has instituted a series of national interventions
over the past decade, including introduction of long-
lasting ITNs, revised recommendations for more effect-
ive first-line anti-malarials [31] and implementation of
intermittent preventive treatment in pregnant women [47]
as well as integrated management of childhood illness [54].
These health system changes, along with socio-economic
improvements, have further reduced malaria morbidity
and mortality in Asembo [31]. Thus, Asembo residents
A)
B)
Figure 5 Entomological inoculation rates (EIRs) and EIR equivalents for Asembo. A) Observed EIRs are based on previously collected
entomological data. EIR equivalents (95% CI) were estimated using AMA-1 and MSP-119 SCRs and previously developed log-log calibration curves.
B) Ratios of EIRs and EIR equivalents relative to baseline values from 1994.
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have experienced a gradual decline in malaria transmission
over many years, making the reductions from the ITN trial
more difficult to pinpoint. Second, despite the documented
reductions in malaria morbidity and mortality over the last
decade, transmission intensity in Asembo remains high
compared to other malaria-endemic areas. When examin-
ing data from other locations where clear break points
have been documented in the age-seroprevalence curves
(e.g., Tanzania [21], Vanuatu [24], Equatorial Guinea [22]),
post-intervention SCRs were generally two to ten times
lower than the values observed for Asembo. It is possible
that transmission intensity remains too high in Asembo for
the reversible catalytic conversion model, combined with
these antigens, to accurately predict shifts in SCR between
age groups. Third, a great deal of short- and long-term mi-
gration occurs in and out of the Lake Victoria region
[43,55,56]. Out of this highly mobile population, it is pos-
sible that many of the individuals surveyed in 2007, 2008
or 2009 did not reside in Asembo during the ITN trial, fur-
ther diminishing the ability to detect a sharp drop in mal-
aria exposure. Fourth, serological evidence of the historic
decline in transmission may be obscured in part by the re-
cent rise in malaria incidence in Asembo since 2008. While
serological data from 2007 (and potentially 2008) would
not have been influenced by this problem, samples from
those two years were small in number and restricted to in-
dividuals aged ≤15 years, which could have hindered the
ability to detect differences in SCR between age groups.
Samples from 2009 were ample and included all ages, but
the rebound in malaria transmission may have obscured
any differences between age groups by disproportionately
increasing seroprevalence in younger individuals.
In addition to limited sample sizes and age groups for
certain years, reliance on past studies that employed dif-
ferent protocols presented multiple challenges. For ex-
ample, serological specimens from 1994 and 2000 were
collected as serum, whereas specimens from 2007 to
2009 were collected as dried blood spots. To be cau-
tious, direct quantitative comparison of ELISA results
between years was minimized by calculating different
seropositivity cut-off values for each year. Unfortunately,
direct comparisons could not be avoided when examin-
ing antibody titres. It should be noted, however, that
Corran et al. [46] reported 93% correlation in antibody
concentrations between paired serum and blood spot
samples from the field, suggesting that both types of
specimens serve as adequate and comparable sources of
anti-malarial antibodies.
Different methods were also employed to measure
EIRs in Asembo over time. Bed net traps, PSCs and
CDC light traps differ in their sensitivity for capturing
malaria vectors [11,57,58], making it difficult to compare
EIRs from one year to the next. This problem extends
far beyond the present study; EIR is the most commonly
used metric of malaria transmission intensity, yet is no-
toriously difficult to standardize [3]. The lack of congru-
ence between EIR equivalents estimated from serological
data and measured EIR values could be due to poor fit
of the calibration curves to Asembo serology data, fail-
ure to standardize EIR measurement techniques, or a
combination of both. In addition, the heterogeneous dis-
tribution of mosquito bites across individuals within a
population is known to introduce discrepancies between
EIR and SCR [14]. Despite these problems, the overall
trend of a dramatic decrease in EIRs and EIR equivalents
from 1994 to the mid 2000s, followed by a small rise in
recent years, is consistent with serological results [31].
Conclusions
Sero-epidemiological tools have proven valuable for
quantifying long-term changes in malaria transmission
in numerous different locations. From the standpoint of
programmatic monitoring, serology is relatively fast and
efficient; finger-prick blood samples can be quickly col-
lected in large numbers and ELISAs are high-throughput
and easily standardized [16,46]. In highly endemic areas,
however, historic reductions in malaria transmission may
be difficult to detect from a single post-intervention sur-
vey using current serological tools, potentially limiting the
utility of these tools for retrospective analyses. Neverthe-
less, in high transmission settings, serological point
measures could be effective as adjunct tools used in
combination with parasite prevalence, as serology pro-
vides information on cumulative incidence and is less
sensitive to seasonal fluctuations. Exploration of differ-
ent malaria antigens or alternative models of popula-
tion seroconversion (e.g., models that take into account
age- or exposure-related changes in seroreversion rates
[48,59-61]) may yield tools that are more informative
for retrospective analyses in high endemicity areas. As
malaria control receives increasing attention and funding,
there will be growing need for tools that can accurately
measure the epidemiological impact of interventions over
extended periods, particularly in high transmission set-
tings where reductions are most difficult to achieve and
sustain.
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